The final, formatted version of the article will be published soon.
REVIEW article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1446085
This article is part of the Research Topic Exploring Oncolytic Virotherapy in Solid Tumor Treatment View all 4 articles
Progression of Oncolytic Virus in Liver Cancer Treatment
Provisionally accepted- 1 University of Michigan, Ann Arbor, United States
- 2 Department of Histology and Embryology, Shandong First Medical University, Jinan, China
- 3 Innovation Practice Center, Changchun University of Chinese Medicine, Changchun, Hebei Province, China
- 4 Institute of Animal Husbandry and Veterinary Medicine, Beijing Academy of Agriculture and Forestry Sciences, Beijing, China
- 5 Institute of Innovation and Entrepreneurship, Zhejiang University of Technology, Zhejiang, Zhejiang Province, China
The liver plays a crucial role in detoxification, metabolism, and nutrient storage. Because liver cancer ranks among the top three leading causes of death globally, there is an urgent need for developing treatment strategies for liver cancer. Although traditional approaches such as radiation, chemotherapy, surgical removal, and transplantation are widely practiced, the number of patients with liver cancer continues to increase rapidly each year. Some novel therapeutics for liver cancer have been studied for many years. In the past decade, oncolytic therapy has emerged, in which viruses selectively infect and destroy cancer cells while sparing normal cells. However, oncolytic virotherapy for liver cancer remains relatively obscure due to the aggressive nature of the disease and the limited effectiveness of treatment. To keep pace with the latest developments in oncolytic tumor therapy for liver cancer, this review summarizes basic science studies and clinical trials conducted within 5 years, focusing on the efficacy and safety profiles of the five most commonly used oncolytic viruses: herpes simplex virus, adenovirus, influenza virus, vaccinia virus, and coxsackievirus.
Keywords: HCC, oncolytic virus, Influenza Virus, Herpes Simplex Virus, adenovirus
Received: 09 Jun 2024; Accepted: 02 Sep 2024.
Copyright: © 2024 Hua, Xuan, Tang, You, Zhao, Qiu, Li, Li, Su and Qu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yanping Su, Department of Histology and Embryology, Shandong First Medical University, Jinan, China
Peng Qu, Innovation Practice Center, Changchun University of Chinese Medicine, Changchun, 130117, Hebei Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.